Orient Securities: The pharmaceuticals and biotechnology industry is expanding overseas, presenting an excellent opportunity to capitalize on contract manufacturing for innovative drugs.

Domestic centralized procurement and healthcare reform policies are gradually becoming more moderate, while international operations, after years of cultivation, have already gained momentum and continue to accelerate overseas expansion.

Zhitong FinanceMay 6 09:16

Aosaikang Obtains License to Develop, Distribute Anti-Tumor Drug in China, Hong Kong, Macau

MT NewswiresDec 30, 2025 21:21

Adlai Nortye Enters Exclusive License Agreement With ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

GlobeNewswireDec 29, 2025 19:00

Is the 'pharmaceutical rally' back? A 460 billion giant turns losses into profits, igniting a surge across Hong Kong and mainland China's innovative drug sector.

Institution: China's innovative drug industry has entered the 2.0 era.

Gelonghui FinanceNov 13, 2025 14:18

Express News | Summary of Shareholding Changes on August 15

BreakingsAug 15, 2025 22:01

Aosaikang (002755.SZ): Zhongyi Weiye plans to reduce its holdings by no more than 2%.

Gelonghui, August 15 | Aosaikang (002755.SZ) announced that its shareholder Zhongyi Weiye Holdings Limited (referred to as "Zhongyi Weiye") holds 120,192,033 shares of the company, accounting for 12.9495% of the total share capital. Zhongyi Weiye plans to reduce its shareholding by no more than 18,563,200 shares, representing no more than 2% of the total share capital of the company, through centralized bidding and block trades within three months after 15 trading days from the date of the announcement.

Gelonghui FinanceAug 15, 2025 20:11